RT Journal Article
SR Electronic
T1 Interferon-α2b treatment for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.06.20042580
DO 10.1101/2020.04.06.20042580
A1 Zhou, Qiong
A1 Chen, Virginia
A1 Shannon, Casey P.
A1 Wei, Xiao-Shan
A1 Xiang, Xuan
A1 Wang, Xu
A1 Wang, Zi-Hao
A1 Tebbutt, Scott J.
A1 Kollmann, Tobias R.
A1 Fish, Eleanor N.
YR 2020
UL http://medrxiv.org/content/early/2020/04/10/2020.04.06.20042580.abstract
AB Background The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China.Methods In this retrospective study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5mU b.i.d.), arbidol (200mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts and blood biochemistry, serum cytokine levels, temperature and blood oxygen saturation levels were recorded for each patient during their hospital stay.Results Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP.Conclusion These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available